Skip to main content

Table 4 Multivariable logistic regression for predictors of receiving ramucirumab as a monotherapy vs. combination therapy

From: Ramucirumab for the treatment of patients with gastric or gastroesophageal junction cancer in community oncology practices

Variable Level N (monotherapy subgroup) Monotherapy ramucirumab odds ratio 95% Lower CI 95% Upper CI Individual effect P value Overall effect P value
Prior treatments for gastric or GEJ cancer prior to ramucirumab initiation: fluoropyrimidine No (reference) 171 (66) < 0.0001
Yes 334 (49) 0.332 0.207 0.532 < 0.0001
Line of therapy of ramucirumab initiation 1 (reference) 15 (4) < 0.0001
2 407 (65) 0.894 0.267 2.997 0.8565
3 58 (31) 4.385 1.210 15.883 0.0244
4+ 18 (13) 9.820 2.015 47.846 0.0047
  1. CI confidence interval, GEJ gastroesophageal junction